Intravascular Administration Sets 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Hospira Inc 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2013-08-15
  • 사례 출판 날짜
    2013-08-15
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
    ICU Medical, Inc. acquired from Pfizer in early 2017, Hospira Infusion Systems, the portion of Hospira dedicated to develop infusion pumps.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: hospira intravascular administration sets the united states food and drug administration (fda) has issued a medical device safety alert concerning intravascular administration sets, manufactured by hospira inc. please see below the list number of the affected products: 14200-04-28: secondary blood set 14203-04-28: blood set 14206-04-28: y-type blood set 14207-04-28: blood set 14210-04-28: plum blood set 14211-04-28: plum blood set 14212-04-28: plum y-type blood set 14217-04-28: y-type blood set 14219-04-28: y-type blood set according to the fda, it was discovered that there was a potential for the piercing pin on certain iso-compliant hospira blood sets to puncture the outer wall of the non-iso-compliant blood bags during insertion of the pin into the blood bag. this can lead to the leakage of blood and health care provider exposure to blood products. a delay of therapy may also occur and in some cases result in serious adverse health consequences or death. at this time, there is no need for customers to discontinue use of or return hospira blood sets. the manufacturer recommends users exercise extreme caution when piercing blood bags with a hospira blood set mentioned above. the affected users are advised to make sure that all instructions for use included with the blood bag and protocol for spiking blood bags are completely followed, to minimize the possibility of puncturing the outer wall of the blood bag. the manufacturer has begun distribution of sets with a blunter, shorter piercing pin than the affected sets. these sets became available in march, 2013. for details, please visit the following fda websites: http://www.Accessdata.Fda.Gov/scripts/enforcement/enforce_rpt-event-detail.Cfm?action=detail&id=65689&w=08142013&lang=eng http://www.Fda.Gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm364973.Htm http://www.Fda.Gov/medicaldevices/safety/listofrecalls/ucm364988.Htm http://www.Fda.Gov/safety/recalls/ucm364935.Htm if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 15 august 2013.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Hospira Intravascular Administration Sets
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • Source
    DH